SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Nutraceutix(nutx .96) inhibits lung cancer! News story
NUTX 176.68+5.1%Dec 26 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
To: sean sullivan who started this subject3/21/2001 3:17:11 PM
From: ksuave   of 57
 
Wednesday March 21, 2:58 pm Eastern Time

Nutraceutix Inc. Makes Available for the First Time D-Glucarate With Patented Controlled Delivery Technology

REDMOND, Wash.--(BW HealthWire)--March 21, 2001-- Nutraceutix Inc. (OTC BB: NUTX - news) introduces for the first time to the nutritional supplement market D-Glucarate Pre-Blend with patented Controlled Delivery Technology (CDT)(TM).

Now manufacturers can pass along to their consumers the healthful benefits of patented Calcium D-Glucarate with the controlled dosage and release of patented CDT(TM). Nutraceutix Inc. offers CDT(TM) D-Glucarate with 12-hour release and CDT(TM) D-Glucarate with 24-hour release in 200mg tablets.

D-Glucarate is the patented form of glucaric acid, a naturally occurring substance in the body that promotes glucuronidation, a process by which the body eliminates toxins. While glucaric acid is found primarily in fruits and cruciferous vegetables, numerous studies indicate that increased levels of D-Glucarate through supplementation are effective in assisting the body in detoxification.

D-Glucarate research has proven so promising that internationally recognized AMC Cancer Research Center, Denver has recommended D-Glucarate's use; the first time the not-for-profit research institution has recommended a dietary supplement.

According to Nutraceutix President and Chief Executive Officer, David Howard, ``CDT(TM) D-Glucarate is the third in our series of patented nutraceutical pre-blends. As more consumers learn the credible health benefits of D-Glucarate, the demand will grow accordingly. CDT(TM) D-Glucarate Pre-Blend allows our manufacturing partners easy-to-use formulations that are safe and efficacious to consumers.

``Patented D-Glucarate Pre-Blend with the added advantage of CDT(TM)'s optimal delivery mechanism add up to a winning combination.''

Currently, Nutraceutix Inc. has licensed the use of Calcium D-Glucarate to more than 40 different companies. Glucona America Inc. of Janesville, Wis., master supplier of D-Glucarate, has developed and implemented a proprietary identification marker in its continuing campaign to protect patented Calcium D-Glucarate from distribution by unlicensed distributors.

The marker creates a chemical ``fingerprint'' that allows the company to accurately and definitively identify its product. This practice reduces the likelihood of fraudulent and inferior product entering the market and reaching consumers.

Nutraceutix Inc. possesses proven technologies and products for the nutraceutical industry. In addition to patented ingredients like Calcium D-Glucarate(TM), Nutraceutix provides patented and proprietary technologies like CDT(TM) Controlled Delivery Technology, MDT(TM) Molecular Dispersion Technology, SET(TM) Self Emulsifying Technology and LiveBac® Probiotics.

Nutraceutix technologies provide distinctive supplements with tangible benefits for the consumer and competitive commercial advantages. For more information on Nutraceutix, please call Stephen Turner, director, Project Management at 800/548-3222, or visit www.nutraceutix.com.

Except for any historical information, the matters discussed in this press release contain forward-looking statements, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. Such statements are subject to a number of assumptions, risks and uncertainties.

Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements.

--------------------------------------------------------------------------------
Contact:

ignite marketing group
Margaret Anderson, 480/785-5252
Margaret@ignitemg.com
www.nutraceutix.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext